Opinion|Videos|November 27, 2024
Navigating Healthcare Access and Decision-Making
Key Takeaways
- Integrating HER2-directed therapies into NSCLC treatment requires alignment with existing protocols and timely updates to decision-making processes.
- Establishing frameworks for rapid incorporation of emerging therapies and fostering adaptive decision-making processes are essential strategies.
An analysis of challenges and strategies for integrating HER2-directed therapies into decision-making for NSCLC, with a focus on timely updates, collaborative efforts among stakeholders, and balancing equitable access with cost management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key challenges in integrating HER2-directed therapies into existing internal decision-making processes for NSCLC?
- What strategies can be employed to ensure timely updates to internal decision-making processes as new HER2-directed therapies emerge?
- How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
5